Clinical Trials on Blood Coagulation Disorders in United Kingdom

Total 82040 results

Royal Free Hospital NHS Foundation Trust

Unknown

Inter Individual Variability in Initiation Pathway Activation and Regulation and Phenotypic Heterogeneity in Patients With Haemophilia A and B (InPath)

Haemophilia

United Kingdom
Baxalta now part of Shire

Terminated

First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients

Hemophilia

United Kingdom
Hampshire Hospitals NHS Foundation Trust

Completed

National Study of a Pharmacokinetic-Focused Educational Package for Patients With Severe Haemophilia A (UK-PK)

Hemophilia A

United Kingdom
Haemnet
Hemab ApS

Recruiting

The Lived Experience of People With Von Willebrand Disease (VWD360)

Von Willebrand Diseases

United Kingdom
Haemnet
BioMarin Pharmaceutical

Completed

Learning to Live With Non-severe Haemophilia

Hemophilia

United Kingdom
East Kent Hospitals University NHS Foundation Trust

Not yet recruiting

Virtual Evaluations of Joint Health Using Wearable Sensors in Persons With Haemophilia (VESPA) (VESPA)

Haemophilia

United Kingdom
Great Ormond Street Hospital for Children NHS Foundation...
University College, London

Completed

What is the Feasibility of the ISTEP Exercise Test in Boys With Haemophilia

Hemophilia

United Kingdom
Hampshire Hospitals NHS Foundation Trust
Uppsala University; University of Wales Cardiff United Kingdom (UK)

Completed

Efficacy and Cost Effectiveness of Pharmacokinetic Dosing in Haemophilia A

Severe Haemophilia A

United Kingdom
Novo Nordisk A/S

Completed

Investigating Safety and Pharmacokinetics of NNC 0128-0000-2011 Compared to NNC 0128-0000-2021 in Healthy Male Subjects

Congenital Bleeding Disorder | Haemophilia A | Haemophilia B

United Kingdom
Haemnet
UniQure Biopharma B.V.

Completed

An Exploration of the Impact of Gene Therapy on the Lives of People With Haemophilia and Their Families (Exigency)

Hemophilia

United Kingdom
Novo Nordisk A/S

Completed

Post-marketing Safety Surveillance of NovoSeven® in Patients With Haemophilia and Inhibitors by Means of the UK Haemophilia Database

Congenital Bleeding Disorder | Haemophilia A | Haemophilia B

United Kingdom
Novo Nordisk A/S

Completed

Investigation of the Pharmacokinetics of NNC172-2021, at Two Different Dose Levels, in Healthy Japanese Subjects

Healthy | Congenital Bleeding Disorder | Haemophilia A | Haemophilia B

United Kingdom
Novo Nordisk A/S

Completed

A Single Dose Trial Investigating Safety and Local Tolerability of Ascending Doses of Long Acting Activated Recombinant Human Factor VII in Healthy Male Volunteers

Healthy | Congenital Bleeding Disorder | Haemophilia A | Haemophilia B

United Kingdom
Novo Nordisk A/S

Completed

A Single Dose Trial of NNC 0155-0000-0004 in Patients With Haemophilia A

Congenital Bleeding Disorder | Haemophilia A

United Kingdom, Malaysia
Haemnet
Roche Chugai

Completed

An Exploration of the Impact of Emicizumab on the Lives of People With Haemophilia and Inhibitors and Their Families (EmiandMe)

Hemophilia A With Inhibitor

United Kingdom
Bio Products Laboratory

Completed

A Study to Investigate Bio Product Laboratory Ltd (BPL's) Factor X in the Prophylaxis of Bleeding in Children <12 Years

Factor X Deficiency

United Kingdom
East Kent Hospitals University NHS Foundation Trust
Great Ormond Street Hospital for Children NHS Foundation Trust; University...

Recruiting

Trial of an Exercise Intervention for Children With Haemophilia (DOLPHIN-II)

Hemophilia | Musculoskeletal Diseases or Conditions | Child, Only

United Kingdom
Pfizer

Completed

Relative Bioavailability Of Two Formulations Of Moroctocog Alfa (AF-CC)

Hemophilia A

United Kingdom, Hungary, Bulgaria
Cwm Taf University Health Board (NHS)
Cardiff Metropolitan University

Recruiting

Extracellular Vesicles and Dysregulated Coagulation in the Prediction of Stroke (PREDICT-EV)

Transient Ischemic Attack | Coagulation Disorder | Stroke, Ischemic

United Kingdom
Novo Nordisk A/S

Enrolling by invitation

Adverse Event Data Collection From External Registries on Nonacog Beta Pegol

Haemophilia B

Netherlands, United Kingdom
University College, London

Recruiting

Liver Biopsy In Haemophilia Gene Therapy

Hemophilia A, Severe | Hemophilia B, Severe

United Kingdom
BioMarin Pharmaceutical

Active, not recruiting

Gene Therapy Study in Severe Haemophilia A Patients (270-201)

Severe Haemophilia A

United Kingdom
Cangene Corporation

Withdrawn

Study of Recombinant Factor IX Product, IB1001, in Previously Treated Subjects With Hemophilia B

Hemophilia B

United Kingdom, United States
Bio Products Laboratory

Terminated

Optivate in People With Von Willebrand Disease Undergoing Surgery

Von Willebrand Disease

Israel, United Kingdom
Bio Products Laboratory

Terminated

A Study With OPTIVATE® in People With Von Willebrand Disease

Von Willebrand Disease

Israel, United Kingdom
Bio Products Laboratory

Completed

A Study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Patients Undergoing Major Surgery.

Haemophilia B

United Kingdom
Haemnet
Hemab ApS

Completed

The Experiences of People Who Live With Glanzmanns Thrombasthenia.

Glanzmann Thrombasthenia

United Kingdom
University College, London
Medical Research Council

Recruiting

Gene Therapy for Haemophilia A. (GO-8)

Hemophilia A

United States, United Kingdom
Baxalta now part of Shire

Terminated

Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Congenital Hemophilia A

Hemophilia A

United States, South Africa, United Kingdom
Eli Lilly and Company
Sigilon Therapeutics, Inc.

Terminated

Safety & Efficacy of Encapsulated Allogeneic FVIII Cell Therapy in Haemophilia A

Hemophilia A

United Kingdom, United States
Novo Nordisk A/S

Terminated

A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia Subjects (explorer™2)

Healthy | Congenital Bleeding Disorder | Haemophilia A

Austria, Spain, United Kingdom, France, Germany
Takeda

Completed

A Study on the Outcomes of Recombinant Von Willebrand Factor on Demand Treatment and Prevention and Treatment of Bleeding During and After Surgery in Adults With Inherited Von Willebrand Disease in the United Kingdom (UK)

Von Willebrand Disease (VWD)

United Kingdom
BioMarin Pharmaceutical

Active, not recruiting

Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5 (GENEr8-AAV5+)

Hemophilia A | Gene Therapy | Blood Disorder | Clotting Disorders

Taiwan, Korea, Republic of, United Kingdom, South Africa
NHS Lothian

Unknown

Evaluation of the Accuracy of the Hemochron Signature Elite Point of Care Device Compared With Laboratory Assay

Blood Coagulation Tests

United Kingdom
Baxalta now part of Shire
Baxter Innovations GmbH

Completed

BAX 855 Dose-Escalation Safety Study

Hemophilia A

Japan, Bulgaria, Germany, United Kingdom
Vega Therapeutics, Inc

Recruiting

Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease

Von Willebrand Diseases

United States, Austria, South Africa, United Kingdom
CSL Behring

Completed

Study of Voncento® in Subjects With Von Willebrand Disease

Von Willebrand Disease

Poland, Germany, Austria, Greece, United Kingdom
Bio Products Laboratory

Terminated

Safety & Efficacy of BPL's High Purity FACTOR X in Treatment of Factor X Deficient Subjects Undergoing Surgery (Ten03)

Factor X Deficiency

United Kingdom, United States, Spain, Turkey
ApcinteX Ltd
Centessa Pharmaceuticals plc

Active, not recruiting

The Safety and Tolerability of SerpinPC in Healthy Men and in Men With Severe Blood Disorders (Haemophilia A and B)

Hemophilia A | Hemophilia B

Georgia, Moldova, Republic of, United Kingdom
Freeline Therapeutics

Terminated

A Long-Term Follow-Up Study of Haemophilia B Patients Who Have Undergone Gene Therapy

Hemophilia B

United Kingdom
Bio Products Laboratory

Completed

A Study to Compare the Pharmacokinetics and Safety of Replenine®-VF, Replenine® or Other Factor IX in Haemophilia B

Haemophilia B

United Kingdom
Bio Products Laboratory

Completed

An Open Study to Investigate the Safety and Efficacy of Optivate® in Severe Haemophilia A Patients.

Haemophilia A

United Kingdom, Poland
Novo Nordisk A/S

Completed

Safety and Pharmacokinetics of Recombinant Factor XIII in Healthy Volunteers

Healthy | Congenital Bleeding Disorder | Congenital FXIII Deficiency

United Kingdom
Novo Nordisk A/S

Completed

Safety and Pharmacokinetics of Recombinant Factor XIII Administration in Healthy Volunteers

Healthy | Congenital Bleeding Disorder | Congenital FXIII Deficiency

United Kingdom
Bayer

Completed

Study of FVIIa Variant BAY86-6150 (B0189) in Subjects With Moderate or Severe Hemophilia Types A or B With or Without Inhibitors (MATCHBOX)

Hemophilia A | Hemophilia B

South Africa, Poland, United Kingdom
Bio Products Laboratory

Completed

An Open Study to Investigate the Safety and Efficacy of Replenine®-VF in Severe Haemophilia B Patients

Haemophilia B

United Kingdom, Poland
Freeline Therapeutics

Terminated

Phase 1/2 Dose Confirmation Study of FLT180a in Hemophilia B

Hemophilia B

United States, United Kingdom
Novo Nordisk A/S

Completed

Activated Recombinant Human Factor VII in Pelvic-acetabular Fracture Reconstruction

Trauma | Acquired Bleeding Disorder

United Kingdom
Ultragenyx Pharmaceutical Inc

Completed

Long-Term Safety, Tolerability, and Efficacy of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B

Hemophilia B

United States, United Kingdom
Novo Nordisk A/S

Completed

Comparison of a Blood Clotting Drug (Recombinant Factor XIII) Produced by Two Different Manufacturers in Healthy Male Subjects

Healthy | Congenital Bleeding Disorder | Congenital FXIII Deficiency

United Kingdom

Clinical Trials on Blood Coagulation Disorders in United Kingdom

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Vietnam

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations